Document is current
Any future updates will be listed below
-
Authors
,
Prohl, Anna K.
Scherrer, Benoit
Tomas-Fernandez, Xavier
Davis, Peter E.
Filip-Dhima, Rajna
Prabhu, Sanjay P.
Peters, Jurriaan M.
Bebin, E. Martina
Krueger, Darcy A.
Northrup, Hope
Wu, Joyce Y.
Sahin, Mustafa
Warfield, Simon K. http://orcid.org/0000-0002-7659-3880
-
Funding
Funding for this research was provided by:
National Institute of Neurological Disorders and Stroke (U01NS082320)
National Institute of Neurological Disorders and Stroke (U01NS082320)
Eunice Kennedy Shriver National Institute of Child Health and Human Development (U01NS082320, U01NS082320)
Intellectual and Developmental Disabilities Research Center (U54HD090255)
National Institutes of Health (R01 NS079788, R01 EB019483, R44 MH086984)
- License Information
-
More Information
Article History
Received: 3 March 2019
Accepted: 11 November 2019
First Online: 16 December 2019
Ethics approval and consent to participate
: All study procedures were approved by the Institutional Review Board at BCH, CCHMC, UAB, UCLA, and UTH, and all subjects provided written informed consent.
: Not applicable.
: AKP, BS, XTF, RFD, JMP, HN, and SKW declare that they have no competing interests.JYW has received research funding from Novartis and GW Pharmaceutical and is an editorial board member of the journal Pediatric Investigation. DAK has received research funding and consulting fees from the Novartis Pharmaceuticals, and additional consulting fees from Mallinckrodt Pharmaceuticals, AXIS Media, and Advance Medical. MS has received research funding from Roche, Novartis, Pfizer, LAM Therapeutics, Rugen, Ibsen, and Neuren and has served on the Scientific Advisory Board of Sage Therapeutics, Roche and Takeda.
